Erythropoietin Augments Antibody Response to DNP in Immunized Mice.

Blood ◽  
2004 ◽  
Vol 104 (11) ◽  
pp. 4232-4232
Author(s):  
Lidor Yeyni ◽  
Odelia Katz ◽  
Sari Prutchi-Sagiv ◽  
Alon Skaat ◽  
Eran Barzilay ◽  
...  
Keyword(s):  
Immune Response ◽  
Initial Phase ◽  
Recombinant Human Erythropoietin ◽  
Keyhole Limpet Hemocyanin ◽  
Hemodialysis Patients ◽  
Humoral Immune ◽  
Human Erythropoietin ◽  
Antibody Levels ◽  
Control Antigen ◽  
Main Growth

Abstract Recombinant human erythropoietin (rHuEpo), the main growth regulator of red blood cells, has been used in clinical practice for the treatment of anemia of various etiologies. Over the last decade several reports have indicated that the action of Epo is not restricted to the erythroid lineage. Studies indicate that rHuEpo treatment may have an immunomodulatory effect on hemodialysis patients. Here we address the effects of rHuEpo on the humoral immune response of mice. Naïve BALB/c mice (two groups of 16 mice each) were immunized with 2mg antigen dinitrophenylated keyhole limpet hemocyanin (DNP-KLH). Concomitant to antigen injection, the mice were injected three times weekly with rHuEpo (180U per injection) or with diluent (control). Blood samples were taken 2 and 4 weeks after immunization and anti-DNP antibody levels were measured by ELISA. Production of anti DNP antibodies increased significantly (1.5–2 fold) in the initial phase of the response (2 weeks following DNP-KLH injection) in mice injected with rHuEpo compared to their counterpart control antigen-injected mice, that received diluent only. These data indicate that erythropoietin may have a role in stimulating the humoral arm of the immune system, suggesting an immunomodulatory and/or immunostimulatory role for rHuEpo and may open new avenues in improving the immune response of immunocompromised patients.

scholarly journals Maternally Derived Antibody Levels Influence on Vaccine Protection against PCV2d Challenge

Animals ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 2231
Author(s):  
István Kiss ◽  
Krisztina Szigeti ◽  
Zalán G. Homonnay ◽  
Vivien Tamás ◽  
Han Smits ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Subunit Vaccine ◽  
Porcine Circovirus Type ◽  
Porcine Circovirus ◽  
Vaccine Protection ◽  
Humoral Immune ◽  
Negative Effect ◽  
Antibody Levels

Piglets from a porcine circovirus type 2 (PCV2) stable farm of low and high levels of maternally derived antibodies (MDA) against PCV2 were vaccinated either with a whole virus type or a PCV2 ORF2 antigen-based commercial subunit vaccine at three weeks of age. Two non-vaccinated groups served as low and high MDA positive controls. At four weeks post vaccination, all piglets were challenged with a PCV2d-2 type virus strain and were checked for parameters related to vaccine protection over a four-week observation period. MDA levels evidently impacted the outcome of the PCV2d-2 challenge in non-vaccinated animals, while it did not have a significant effect on vaccine-induced protection levels. The humoral immune response developed faster in the whole virus vaccinates than in the subunit vaccinated pigs in the low MDA groups. Further, high MDA levels elicited a stronger negative effect on the vaccine-induced humoral immune response for the subunit vaccine than for the whole virus vaccine. The group-based oral fluid samples and the group mean viraemia and faecal shedding data correlated well, enabling this simple, and animal welfare-friendly sampling method for the evaluation of the PCV2 viral load status of these nursery piglets.

scholarly journals Dynamics of humoral immune response in pregnant mares and foals vaccinated with Theileria equi recombinant EMA-2

2018 ◽  
Vol 38 (6) ◽  
pp. 1105-1109
Author(s):  
Alice C. Santos ◽  
Fábio P.L. Leite ◽  
Ana M. Vianna ◽  
Guilherme B. Weege ◽  
Ilusca S. Finger ◽  
...  
Keyword(s):  
Immune Response ◽  
Humoral Immune Response ◽  
Fold Increase ◽  
Serum Levels ◽  
Vaccination Schedule ◽  
Theileria Equi ◽  
Humoral Immune ◽  
Baseline Values ◽  
Antibody Levels ◽  
First Time

ABSTRACT: Theileria equi is an infectious hemoprotozoan agent of equine piroplasmosis, a disease that has severe economic and sanitary impact internationally. In addition to its common clinical features, piroplasmosis can cause gestational losses and neonatal damage, which makes neonates susceptible to this disease. The aim of this study was to evaluate the dynamics of humoral immune response to recombinant EMA-2 of T. equi in pregnant mares and foals, as well as the transfer of vaccine antibodies through the colostrum ingested by sucking foals. For vaccine production, the EMA-2 expression gene was cloned and expressed in the yeast species, Pichia pastoris. Thirty-six horses were used, of which 18 were pregnant mares and 18 were foals. The mares were divided into control and vaccinated groups, and the vaccinated group received three doses of rEMA-2 every 21 days starting at 300 days of gestation. Foals from vaccinated and control groups were evaluated until the sixth month of life. The production of antibodies by foals on the rEMA-2 vaccination schedule was also evaluated from the second month of life. Foals in the vaccinated group had received three doses of the vaccine every 21 days. The method used to evaluate serum and colostrum samples was indirect ELISA, and plates were sensitized with the rEMA-2 protein. At the end of the vaccination schedule, vaccinated mares showed a 2.3-fold increase in antibody levels when compared to baseline values. The colostrum of vaccinated mares presented antibody levels of 1.0432±0.33. Foals delivered by vaccinated mares presented levels of antibodies greater than those of foals delivered by control mares after their first time sucking (at about twelve hours after birth). Foals vaccinated in the second month of life showed an 8.3-fold increase in antibody levels when compared to baseline values. The vaccination schedule with rEMA-2 was able to stimulate humoral immunity in pregnant mares. Vaccine immunoglobins were concentrated in the colostrum of vaccinated mares and foals delivered by these mares showed an increase in serum levels of vaccine antibodies after the first-time sucking.

Treatment of the Anemia of Hemodialysis Patients with Recombinant Human Erythropoietin

1988 ◽  
Vol 11 (4) ◽  
pp. 249-254 ◽  
Author(s):  
R.M. Schaefer ◽  
B. Kuerner ◽  
M. Zech ◽  
G. Denninger ◽  
C. Borneff ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Antibody Formation ◽  
Hemodialysis Patients ◽  
Dialysis Session ◽  
Allergic Reactions ◽  
Human Erythropoietin ◽  
Major Organ ◽  
Baseline Values ◽  
Organ Dysfunctions

Fifteen long-term hemodialysis patients suffering from stable anemia received recombinant human erytheropoietin (r-huEPO). The hormone was given intravenously at the end of each dialysis session starting with a dose of 24 IU/kg. This dose was doubled when hemoglobin levels did not rise within 2 weeks. The number of reticulocytes started to increase after 14 days of treatment. The hematocrit rose from baseline values of 23.7 ± 1.2% to 32.4 ± 1.3% after 24 weeks of treatment. In parallel, hemoglobin values increased from 7.3 ± 0.3 g/100 ml to 10.1 ± 0.4 g/100 ml. As for side effects, 3 patients developed hypertension and 2 patients suffered from occlusions of their arterio-venous fistulas. There was no evidence of major organ dysfunctions, toxic effects, allergic reactions, or antibody formation. These data show that rHuEPO is able to correct the anemia of patients undergoing hemodialysis treatment.

scholarly journals Effect of Recombinant Human Erythropoietin on Reticulocyte Age in Hemodialysis Patients

Nephron ◽  
1992 ◽  
Vol 62 (3) ◽  
pp. 366-367 ◽  
Author(s):  
P. Zachée ◽  
L. Van Hove ◽  
D. Hauglustaine ◽  
L. Veressen ◽  
M.A. Boogaerts
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Human Erythropoietin

Quality of Life Improvements in Capd Patients Treated with Subcutaneously Administered Erythropoietin for Anemia

1992 ◽  
Vol 12 (1) ◽  
pp. 40-42 ◽  
Author(s):  
Juliet Auer ◽  
Gail Simon ◽  
Judith Stevens ◽  
Paul Griffiths ◽  
Deborah Howarth ◽  
...  
Keyword(s):  
Social Life ◽  
Recombinant Human Erythropoietin ◽  
Nottingham Health Profile ◽  
Hemodialysis Patients ◽  
Health Profile ◽  
Emotional Wellbeing ◽  
Household Tasks ◽  
Human Erythropoietin ◽  
Before And After

Twenty -two continuous ambulatory peritoneal dialysis (CAPD) patients, mean age 48 years, at 3 U.K. renal units were assessed with the Nottingham Health Profile (N HP) before and after treatment with recombinant human erythropoietin (r-HuEPO). Mean (SD) hemoglobin (Hb) at baseline was 7.5 (1.0) gIn/dl and 10.8 (1.5) gIn/dl at retest. There were significant improvements in energy (p<0.0001), social life (p<0.005), relationships at home (p<0.05) and leisure pursuits (p<0.05). Twelve patients, mean age 51 years, who had already completed more than 9 months on r-HuEPO treatment were reassessed to determine the changes sustained. Mean (SD) Hb at second retest was 12.8 (1.3) gm/dl. Improvement in energy continued to be significant, and emotional wellbeing showed further improvement. Problems with household tasks, which had not shown significant improvement at Test B, were now considerably reduced (p=0.016). The study showed far-reaching benefits similar to those reported in hemodialysis patients, in a population with a higher mean age and higher potential coexisting illness or disability than most reported hemodialysis studies.

Long-Term Effects of Recombinant Human Erythropoietin on Macro-and Microcirculation in Chronic Hemodialysis Patients

1993 ◽  
Vol 11 (4) ◽  
pp. 237-247 ◽  
Author(s):  
J.J.J.M. Wirtz ◽  
K.M.L. Leunissen ◽  
W. van Kuijk ◽  
E.C. Cheriex ◽  
D.W. Slaaf ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Long Term Effects ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document